GC012F
1 clinical trial
1 product
3 abstracts
1 indication
Indication
Multiple MyelomaAbstract
CD19/BCMA dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin lymphoma: An update.Org: Gracell Biotechnologies Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Clinical trial
A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-03-01
Abstract
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).Org: Gracell Biotechnologies Ltd,
Abstract
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.Org: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Gracell Biotechnologies Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Product
GC012F